Carlos A. Vargas, MD, discusses updated survival outcomes, safety, and the mechanism of SYNC-T SV-102, an investigational in situ immunotherapy for metastatic prostate cancer.
|Videos|November 11, 2022
New LUGPA president discusses this year's meeting and 2023 goals
Author(s)Urology Times staff
"We have more younger members here at the annual meeting than we've ever had before. We want to make that a priority," says Evan R. Goldfischer, MD, MBA, FACS.
Advertisement
Evan R. Goldfischer, MD, MBA, FACS, who officially began his term as LUGPA president, discusses highlights from the
Advertisement
Related to this article
Perioperative durvalumab (Imfinzi) plus neoadjuvant enfortumab vedotin-ejfv (Padcev) cut the risk of EFS events by 49% and death by 42% in cisplatin-ineligible MIBC.
The PROTEUS substudy addresses a key limitation of the main study, which had no surgery-alone control arm.
At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.
Take a look through some of the notable data presentations at this year's ESMO Congress.
Advertisement
Advertisement
Trending on Urology Times
1
PROTEUS Substudy: Perioperative apalutamide plus ADT improves EFS vs surgery alone
2
VOLGA: Durvalumab plus enfortumab vedotin improves EFS, OS in MIBC
3
Adding perioperative pembrolizumab to chemotherapy does not improve EFS in MIBC
4
In situ immunotherapy shows encouraging survival findings in prostate cancer
5